Panel Discussion: Harnessing the Strength of Diversity in Clinical Trials
Anthony Lozama
Medical Director, Novartis Pharmaceuticals
This panel on diversity in clinical trials explored the vital role that diverse populations play in advancing medical research and improving health outcomes. Experts discussed the benefits of diverse trials, such as improved drug efficacy across different populations and better safety profiles alongside strategies for overcoming barriers to participation, ensuring inclusive recruitment practices, and fostering trust within underrepresented communities. The session highlighted real-world examples and provided actionable steps to make clinical trials more equitable and representative.
Dr. Lozama is currently a Medical Director for Cardiovascular Disease at Novartis Pharmaceuticals. He received his PhD in Medicinal and Organic Chemistry from the University of Iowa with a focus on drug design for the central nervous system. He then completed his postdoctoral training in Synthetic Organic Chemistry and Immunology at the Scripps Research Institute working on novel agents for the treatment of breast and prostate cancer. Upon entering industry, Dr. Lozama worked for several years in close conjunction with the Bill and Melinda Gates Foundation on infectious disease diagnostics before transitioning to pharma and medical affairs, 1st at Teva and then Novartis Pharmaceuticals in where he took on roles of increasing responsibility. Dr. Lozama also recently served for several years as the Chair of the NIH study section from Drug Design and Molecular Pharmacology. Dr. Lozama has a passion for translational science and removing barriers to care including championing efforts within the health equity space and diversity within clinical trials.